Shots:

• The approval is based on clinical trial involves assessing Posimir (4mg) vs PBO (12mg) in patients in patients undergoing arthroscopic subacromial decompression surgery with an intact rotator cuff for the first 72hrs.
• The results demonstrated an improvement in both primary outcome measures i.e. 20% reduction in mean pain intensity on a 0-10 point pain scale; 67% reduction in IV morphine-equivalent rescue opioid use
• Posimir is the only approved sustained-release bupivacaine product indicated for up to 72hours of post-surgical analgesia from a single application

 ­ Ref: Durect | Image: Reedland Capital Partners